Online inquiry

IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5134MR)

This product GTTS-WQ5134MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL1RAP gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001167928.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3556
UniProt ID Q9NPH3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5134MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10948MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ11045MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ878MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ8130MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ2501MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ3933MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ13845MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ9227MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW